中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

5327 records (took 0.035 seconds)

    Materials and methods relating to dosage regimen design
    52.
    发明授权
    Materials and methods relating to dosage regimen design 有权

    公开(公告)号：US12094586B2

    公开(公告)日：2024-09-17

    申请号：US16196883

    申请日：2018-11-20

    Applicant: Hoffmann-La Roche Inc.

    Inventor： Hans Peter Grimm ,  Benjamin Ribba ,  Volker Teichgräaeber

    IPC: G16H20/10 ,  G16H50/50

    CPC classification number: G16H20/10 ,  G16H50/50

    Abstract: The present invention provides materials and methods for determining optimal dosage regimens for therapeutic agents. In particular, the invention relates to dosage regimens for therapeutic agents capable of targeting IL-2 receptor, preferably interleukin 2 (IL2)-based therapeutic agents. The methods of the invention allow general dosage regimens to be determined for new IL-2R targeted therapeutic agents but also specifically tailored dosage regimens to be achieved for individuals being treated with IL-2R targeted therapeutic agents.

    METHODS AND COMPOSITIONS FOR TREATING CANCER
    54.
    发明公开
    METHODS AND COMPOSITIONS FOR TREATING CANCER 审中-公开

    公开(公告)号：US20240287182A1

    公开(公告)日：2024-08-29

    申请号：US18402031

    申请日：2024-01-02

    Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

    Inventor： Christoph MARKERT ,  Raymond D. MENG ,  Merlind MUECKE ,  Shiraj SEN ,  Volker TEICHGRAEBER ,  Volker Andreas WIEBKING ,  Edward Namserk CHA ,  Christopher Roland COTTER ,  Michelle Yuri DORAL

    IPC: C07K16/28 ,  A61K39/00 ,  A61P35/04

    CPC classification number: C07K16/2818 ,  A61P35/04 ,  C07K16/2803 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/76

    Abstract: This invention relates to methods and compositions for use in treating cancer in a subject. For example, the invention relates to methods and compositions for use in treating esophageal cancer or colorectal cancer (CRC) (e.g., metastatic CRC (e.g., microsatellite instability (MSI) high (MSI-H) metastatic CRC)) in a subject by administering to the subject an anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antagonist antibody (e.g., tiragolumab) and a PD-1 axis binding antagonist (e.g., atezolizumab); methods and compositions for use in treating metastatic CRC (e.g., MSI-H metastatic CRC) in a subject by administering to the subject an anti-TIGIT antagonist antibody (e.g., tiragolumab), a PD-1 axis binding antagonist (e.g., atezolizumab), and an anti-VEGF antibody (e.g., bevacizumab); methods and compositions for use in treating melanoma in a subject by administering to the subject a bispecific antibody targeting programmed cell death protein 1 (PD-1) and lymphocyte activation gene-3 (LAG3), optionally with an anti-TIGIT antagonist antibody (e.g., tiragolumab); and methods and compositions for use in treating a CD20-positive cell proliferative disorder (e.g., non-Hodgkin's lymphoma (NHL); e.g., relapsed or refractory NHL) in a subject by administering to the subject a bispecific antibody targeting CD20 and CD3 (mosunetuzumab) and an anti-TIGIT antagonist antibody (e.g., tiragolumab), optionally with a PD-1 axis binding antagonist (e.g., atezolizumab).

Patent Agency Ranking